<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharmacology on ScienceChronicle</title>
    <link>https://www.ScienceChronicle.org/tags/pharmacology/</link>
    <description>Recent content in Pharmacology on ScienceChronicle</description>
    <generator>Hugo -- gohugo.io</generator>
    <lastBuildDate>Thu, 18 May 2023 10:46:31 +0000</lastBuildDate><atom:link href="https://www.ScienceChronicle.org/tags/pharmacology/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Hydroxylized Mometasone Furoate Could Diminish Adverse Effects of Topical Psoriasis Treatment</title>
      <link>https://www.ScienceChronicle.org/news/hydroxylized-mometasone-furoate-diminish-adverse-effects-topical-psoriasis-treatment/</link>
      <pubDate>Thu, 18 May 2023 10:46:31 +0000</pubDate>
      
      <guid>https://www.ScienceChronicle.org/news/hydroxylized-mometasone-furoate-diminish-adverse-effects-topical-psoriasis-treatment/</guid>
      <description>Topical psoriasis is a chronic inflammatory skin disease that affects millions worldwide and can significantly reduce a patientâ€™s quality of life. Corticosteroids, such as mometasone furoate, are often used to alleviate the symptoms of psoriasis. However, the use of these medications can have adverse effects, such as skin atrophy and telangiectasia. A recent study conducted in South California, USA, aimed to explore whether hydroxylated mometasone furoate could effectively treat psoriasis while diminishing these adverse effects.</description>
    </item>
    
  </channel>
</rss>
